Reporting owner · Q3 2026 · CIK 1877589

Samaha Eli: insider trades.

Samaha Eli reported 6 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($5.9M), across 2 companies.

Transactions
6
Purchases (P)
0
Sales (S)
5
Companies
2
Name as filed
Samaha Eli

Companies

CompanyRelationshipTransactions
Theravance Biopharma, Inc. (TBPH)TenPercentOwner5
Stagwell Inc (STGW)Director1

Transactions

6 non-derivative rows. Shares and prices as filed.
DateCompanyCodeSharesPriceOwned afterFiling
2026-07-07Theravance Biopharma, Inc.S5,564$17.179,167,489Form 4
2026-07-06Theravance Biopharma, Inc.S1,400$17.049,173,053Form 4
2026-07-01Stagwell IncA2,691$7.43170,764Form 4
2026-07-01Theravance Biopharma, Inc.S37,799$179,174,453Form 4
2026-06-30Theravance Biopharma, Inc.S25,027$17.139,212,252Form 4
2026-06-29Theravance Biopharma, Inc.S273,871$17.239,237,279Form 4

Questions

What stock did Samaha Eli buy or sell?

Samaha Eli reported 6 non-derivative transactions on 3 SEC ownership filings in Q3 2026: 0 open-market purchases and 5 sales ($5.9M), across 2 companies.

Is Samaha Eli the same person as other filers with this name?

This page covers SEC CIK 1877589 only. The SEC assigns each reporting owner a CIK, and people with the same name have different CIKs.

Source: SEC Insider Transactions Data Sets, Q3 2026. Reported as filed; we do not assess intent, performance or compliance. All filings for this CIK on SEC.gov.

Plain-text version for agents and LLMs: /insiders/samaha-eli-1877589.md

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.